Brokerages Set SOPHiA GENETICS SA (NASDAQ:SOPH) Target Price at $9.00

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have been given a consensus rating of “Hold” by the five analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $9.00.

Several brokerages recently weighed in on SOPH. HC Wainwright assumed coverage on SOPHiA GENETICS in a research note on Monday, July 20th. They issued a “buy” rating and a $12.00 price target for the company. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research reiterated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th.

SOPHiA GENETICS Trading Down 0.4%

Shares of NASDAQ:SOPH opened at $5.55 on Thursday. The business’s 50-day moving average is $5.44 and its 200 day moving average is $5.09. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. SOPHiA GENETICS has a 1 year low of $2.92 and a 1 year high of $6.77. The firm has a market capitalization of $465.59 million, a P/E ratio of -10.67 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The company had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. On average, research analysts predict that SOPHiA GENETICS will post -0.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Ross Muken sold 9,838 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the sale, the chief executive officer owned 670,651 shares of the company’s stock, valued at $3,500,798.22. This represents a 1.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00. Following the sale, the insider owned 223,387 shares of the company’s stock, valued at $1,264,370.42. This represents a 2.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 221,092 shares of company stock valued at $1,250,070 over the last 90 days. Insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC boosted its stake in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the period. Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the first quarter valued at about $2,157,000. Royce & Associates LP purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $2,009,000. Finally, Sei Investments Co. purchased a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at approximately $1,772,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.